Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mathieu Le Gars

Showing results (31-40 of 45) with videos related to

Pageof 5
Sort By:
Vaccine|June 6, 2022
Durable antibody responses elicited by 1 dose of Ad26.COV2.S and substantial increase after boosting: 2 randomized clinical trialsJerald Sadoff, Mathieu Le Gars, Boerries Brandenburg, et al.
Nature Communications|October 8, 2021
SARS-CoV-2 binding and neutralizing antibody levels after Ad26.COV2.S vaccination predict durable protection in rhesus macaquesRamon Roozendaal, Laura Solforosi, Daniel J Stieh, et al.
JAMA Network Open|August 10, 2022
Durability of Heterologous and Homologous COVID-19 Vaccine BoostsC Sabrina Tan, Ai-Ris Y Collier, Jingyou Yu, et al.
The New England Journal of Medicine|February 9, 2022
Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.SJerald Sadoff, Glenda Gray, An Vandebosch, et al.
Iscience|September 6, 2023
Comparative analysis of spike-specific IgG Fc glycoprofiles elicited by adenoviral, mRNA, and protein-based SARS-CoV-2 vaccinesJulie Van Coillie, Tamas Pongracz, Tonći Šuštić, et al.
The New England Journal of Medicine|January 13, 2021
Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 VaccineJerald Sadoff, Mathieu Le Gars, Georgi Shukarev, et al.
The New England Journal of Medicine|April 21, 2021
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19Jerald Sadoff, Glenda Gray, An Vandebosch, et al.
Nature|June 9, 2021
Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humansGalit Alter, Jingyou Yu, Jinyan Liu, et al.
NPJ Vaccines|January 11, 2022
Passive transfer of Ad26.COV2.S-elicited IgG from humans attenuates SARS-CoV-2 disease in hamstersLisa H Tostanoski, Abishek Chandrashekar, Shivani Patel, et al.
Research Square|July 3, 2023
Quantifying how single dose Ad26.COV2.S vaccine efficacy depends on Spike sequence featuresCraig Magaret, Li Li, Allan deCamp, et al.
Pageof 5

Showing results (31-40 of 45) with videos related to

Sort By:
Pageof 5
Vaccine|June 6, 2022
Durable antibody responses elicited by 1 dose of Ad26.COV2.S and substantial increase after boosting: 2 randomized clinical trialsJerald Sadoff, Mathieu Le Gars, Boerries Brandenburg, et al.
Nature Communications|October 8, 2021
SARS-CoV-2 binding and neutralizing antibody levels after Ad26.COV2.S vaccination predict durable protection in rhesus macaquesRamon Roozendaal, Laura Solforosi, Daniel J Stieh, et al.
JAMA Network Open|August 10, 2022
Durability of Heterologous and Homologous COVID-19 Vaccine BoostsC Sabrina Tan, Ai-Ris Y Collier, Jingyou Yu, et al.
The New England Journal of Medicine|February 9, 2022
Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.SJerald Sadoff, Glenda Gray, An Vandebosch, et al.
Iscience|September 6, 2023
Comparative analysis of spike-specific IgG Fc glycoprofiles elicited by adenoviral, mRNA, and protein-based SARS-CoV-2 vaccinesJulie Van Coillie, Tamas Pongracz, Tonći Šuštić, et al.
The New England Journal of Medicine|January 13, 2021
Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 VaccineJerald Sadoff, Mathieu Le Gars, Georgi Shukarev, et al.
The New England Journal of Medicine|April 21, 2021
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19Jerald Sadoff, Glenda Gray, An Vandebosch, et al.
Nature|June 9, 2021
Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humansGalit Alter, Jingyou Yu, Jinyan Liu, et al.
NPJ Vaccines|January 11, 2022
Passive transfer of Ad26.COV2.S-elicited IgG from humans attenuates SARS-CoV-2 disease in hamstersLisa H Tostanoski, Abishek Chandrashekar, Shivani Patel, et al.
Research Square|July 3, 2023
Quantifying how single dose Ad26.COV2.S vaccine efficacy depends on Spike sequence featuresCraig Magaret, Li Li, Allan deCamp, et al.
Pageof 5